All In Biotech

Drug Trial Radar · NCT05232929

Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

Long-term Follow-up Study of Patients With Spinal Muscular Atrophy Receiving Risdiplam Treatment

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

403

Actual

Start

Mar 29, 2022

Primary completion

Oct 9, 2026

Study completion Oct 9, 2026

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Information (USPI) in adult and pediatric participants with SMA. In this study, participants will be followed for approximately 24 months from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study if they agree to continue participating in the follow-up assessments. An optional sub-study was planned to assess the feasibility, acceptability, and adherence of remote assessment of motor and bulbar functions in participants with SMA using wearable and smartphone-based biosensors. This substudy was withdrawn upon implementation of protocol version 4.

Conditions

  • Spinal Muscular Atrophy

Interventions

  • RisdiplamDrug

    Risdiplam taken by participants as prescribed by their physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)Time frame: From enrollment up to the duration of the study or until withdrawal of consent, loss to follow-up, or death (up to approximately 24 months)

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Loma Linda University Health Care

    Loma Linda, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • University California - Irvine

    Orange, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of Colorado

    Aurora, Colorado

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Hospital

    Washington D.C., District of Columbia

  • Nemour's Children's Hospital, Florida

    Orlando, Florida

  • All Children's Research Institute, Inc.

    St. Petersburg, Florida

  • Advent Health Orlando

    Winter Park, Florida

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Norton Children's Hospital

    Louisville, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Pediatric Rehabilitation Center

    Ann Arbor, Michigan

  • Helen DeVos Children's Hospital at Spectrum Health

    Grand Rapids, Michigan

  • Gillette Children's Specialty Healthcare

    Minnetonka, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University;Wash Uni. Sch. Of Med

    St Louis, Missouri

  • NYU Hospital for Joint Diseases

    New York, New York

  • Columbia University Med Center

    New York, New York

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Texas at Austin Health sciences, Dell Medical School

    Austin, Texas

  • Neurology & Neuromuscular Care Center

    Denton, Texas

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • Methodist Children's Hospital of South Texas

    San Antonio, Texas

  • University Of Utah

    Salt Lake City, Utah

  • University of Virginia Children?s Hospital

    Charlottesville, Virginia

  • MultiCare Health System Institute for Research and Innovation

    Tacoma, Washington

  • UBC (Remote Coordinating Center, no physical facility)

    Morgantown, West Virginia

  • Childrens Hospital of Wisconsin

    Milwaukee, Wisconsin

  • Instituto de Rehabilitación del Caribe

    Santurce, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.